Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Shares of Xencor (XNCR) gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs. Xencor Shares Favorable Updates on Oncology Pipeline The company announced favorable initial results from two early-stage oncology programs. Initial data from an ongoing phase I study showed signs of anti-tumor activity for its investigational ENPP3 x CD3 bispecific antibody XmAb819 in patients with clear cell ...